View in EDS

Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story.

Saved in:
Bibliographic Details
Title: Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story.
Authors: Verheijden RJ; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., de Groot JS; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Fabriek BO; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Hew MN; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., May AM; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Suijkerbuijk KPM; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Feb 10; Vol. 43 (5), pp. 616-619. Date of Electronic Publication: 2024 Nov 15.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39546742
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Verheijden+RJ%22">Verheijden RJ</searchLink>; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Groot+JS%22">de Groot JS</searchLink>; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Fabriek+BO%22">Fabriek BO</searchLink>; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Hew+MN%22">Hew MN</searchLink>; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22May+AM%22">May AM</searchLink>; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Suijkerbuijk+KPM%22">Suijkerbuijk KPM</searchLink>; Rik J. Verheijden, MSc, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Jolien S. de Groot, MD, PhD, Babs O. Fabriek, PhD, and Miki N. Hew, MD, PhD, Medicines Evaluation Board, Utrecht, the Netherlands; Anne M. May, PhD, Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; and Karijn P.M. Suijkerbuijk, MD, PhD, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2025 Feb 10; Vol. 43 (5), pp. 616-619. <i>Date of Electronic Publication: </i>2024 Nov 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39546742
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO-24-02234
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 616
    Titles:
      – TitleFull: Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Verheijden RJ
      – PersonEntity:
          Name:
            NameFull: de Groot JS
      – PersonEntity:
          Name:
            NameFull: Fabriek BO
      – PersonEntity:
          Name:
            NameFull: Hew MN
      – PersonEntity:
          Name:
            NameFull: May AM
      – PersonEntity:
          Name:
            NameFull: Suijkerbuijk KPM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 02
              Text: 2025 Feb 10
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1